The LDL-C/Apo B predicts coronary atherosclerotic heart disease in non-diabetic patients without high LDL-C

Abstract

The apolipoprotein B (Apo B), Apo B/A1 ratio, lipoprotein (a), and low-density lipoprotein cholesterol (LDL-C)/Apo B ratio are associated with coronary artery disease (CAD). However, the association between these parameters and CAD in non-diabetic patients without high LDL-C levels is unclear. Our goal was to assess which parameter was most strongly associated with CAD in non-diabetic patients without high LDL-C levels. This study included 487 non-diabetic patients with LDL-C < 130.0 mg/dL. All the patients underwent coronary computed tomographic angiography. We assessed the significance of each continuous atherogenic biomarker for CAD (incidence of coronary plaque and revascularization) without and after adjustment for standard risk factors. The LDL-C/Apo B ratio and lipoprotein (a) were significant risk factors for the incidence of coronary plaque on multivariate analysis after adjustment for standard risk factors. The LDL-C/Apo B ratio was significant for the incidence of revascularization in multivariate analysis after adjustment for standard risk factors. The degree of coronary calcification and plaque burden according to the tertile of LDL-C/Apo B showed significant differences between the groups. Our data indicate that LDL-C/Apo B ratio is the most predictive parameter for coronary atherosclerosis in non-diabetic patients without high LDL-C levels.

The LDL-C/ApoB ratio predicts cardiovascular and all-cause mortality in the general population

“…Previous studies [ 19 – 21 ] have mainly focused on the association between LAR and the development of cardiovascular disease. To our knowledge, only the study by Drexel et al [ 22 ] and Silbernagel et al [ 23 ] have evaluated the prognostic value of LAR for death.…”

“…Previous studies on the role of LAR in diseases have mainly focused on evaluating atherosclerotic lipid profiles and predicting the risk of suffering from CVD [ 19 – 21 ]. A recent prospective cohort study [ 22 ] found that LAR can predict adverse cardiovascular outcomes among individuals with established atherosclerosis.…”

Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment

“…Their research included non-diabetic patients, extending the use of this biomarker outside the borders specified in the ESC guidelines. However, in their study, apoB alone did not offer any additional predictive power for coronary stenosis over LDL-C [ 82 ].…”